NASDAQ:KRTX

Karuna Therapeutics News Headlines

$115.44
+4.39 (+3.95 %)
(As of 04/14/2021 12:00 AM ET)
Add
Compare
Today's Range
$111.60
Now: $115.44
$119.19
50-Day Range
$112.02
MA: $119.72
$133.08
52-Week Range
$69.00
Now: $115.44
$146.97
Volume179,991 shs
Average Volume207,323 shs
Market Capitalization$3.12 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.07

Headlines

Karuna Therapeutics (NASDAQ KRTX) News Headlines Today

SourceHeadline
Karuna Therapeutics (NASDAQ:KRTX) Research Coverage Started at Bank of AmericaKaruna Therapeutics (NASDAQ:KRTX) Research Coverage Started at Bank of America
marketbeat.com - March 29 at 8:51 AM
Andrew Craig Miller Sells 5,000 Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX) StockAndrew Craig Miller Sells 5,000 Shares of Karuna Therapeutics, Inc. (NASDAQ:KRTX) Stock
americanbankingnews.com - April 14 at 4:36 PM
Karuna Therapeutics (NASDAQ:KRTX) Shares Gap Down to $119.94Karuna Therapeutics (NASDAQ:KRTX) Shares Gap Down to $119.94
americanbankingnews.com - April 9 at 11:03 AM
Karuna Therapeutics (NASDAQ:KRTX) Coverage Initiated at Bank of AmericaKaruna Therapeutics (NASDAQ:KRTX) Coverage Initiated at Bank of America
americanbankingnews.com - March 29 at 9:28 AM
Karuna Therapeutics (NASDAQ:KRTX) Now Covered by Analysts at Bank of AmericaKaruna Therapeutics (NASDAQ:KRTX) Now Covered by Analysts at Bank of America
americanbankingnews.com - March 22 at 9:48 AM
Karuna Therapeutics Inc (KRTX) COO Andrew Craig Miller Sold $592,400 of SharesKaruna Therapeutics Inc (KRTX) COO Andrew Craig Miller Sold $592,400 of Shares
finance.yahoo.com - March 12 at 9:02 PM
Karuna Therapeutics Announces Pricing of Public Offering of Common StockKaruna Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - March 1 at 11:01 PM
Karuna Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides General Business UpdateKaruna Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results and Provides General Business Update
finance.yahoo.com - February 25 at 10:36 AM
Karuna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in SchizophreniaKaruna Therapeutics Announces New England Journal of Medicine Publication of Data from EMERGENT-1 Phase 2 Trial Evaluating KarXT in Schizophrenia
finance.yahoo.com - February 24 at 7:08 PM
KRTX Feb 2021 155.000 callKRTX Feb 2021 155.000 call
au.finance.yahoo.com - February 12 at 11:59 PM
KRTX Mar 2021 55.000 putKRTX Mar 2021 55.000 put
au.finance.yahoo.com - February 12 at 6:59 PM
KRTX Mar 2021 100.000 putKRTX Mar 2021 100.000 put
au.finance.yahoo.com - February 11 at 6:03 PM
Insider Sells Karuna Therapeutics StockInsider Sells Karuna Therapeutics Stock
finance.yahoo.com - February 10 at 7:54 PM
Noteworthy Tuesday Option Activity: IGT, SBNY, KRTXNoteworthy Tuesday Option Activity: IGT, SBNY, KRTX
nasdaq.com - February 9 at 6:57 PM
Karuna Therapeutics to Participate at 10th Annual SVB Leerink Global Healthcare ConferenceKaruna Therapeutics to Participate at 10th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 2 at 8:30 AM
KRTX Feb 2021 100.000 putKRTX Feb 2021 100.000 put
au.finance.yahoo.com - January 31 at 6:29 PM
Karuna Therapeutics Announces Appointment of Ronald Marcus, M.D., as Senior Vice President of MedicalKaruna Therapeutics Announces Appointment of Ronald Marcus, M.D., as Senior Vice President of Medical
finance.yahoo.com - January 26 at 9:13 AM
Karuna Therapeutics to Participate in the ICR Conference 2021Karuna Therapeutics to Participate in the ICR Conference 2021
finance.yahoo.com - January 7 at 7:24 AM
Karuna Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare ConferenceKaruna Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 5 at 8:47 AM
Karuna Therapeutics Appoints Denice Torres, J.D., to its Board of DirectorsKaruna Therapeutics Appoints Denice Torres, J.D., to its Board of Directors
finance.yahoo.com - December 22 at 8:56 AM
Is KRTX A Good Stock To Buy Now?Is KRTX A Good Stock To Buy Now?
finance.yahoo.com - December 16 at 9:45 AM
Karuna Therapeutics Appoints David Wheadon, M.D., to Its Board of DirectorsKaruna Therapeutics Appoints David Wheadon, M.D., to Its Board of Directors
finance.yahoo.com - December 3 at 9:30 AM
Savvy Companies Making Moves in Drug-Development SpaceSavvy Companies Making Moves in Drug-Development Space
finanznachrichten.de - November 12 at 10:07 AM
Karuna Therapeutics to Present at the Stifel 2020 Virtual Healthcare ConferenceKaruna Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
finance.yahoo.com - November 10 at 9:52 AM
Karuna Therapeutics Reports Third Quarter 2020 Financial Results and Provides General Business UpdateKaruna Therapeutics Reports Third Quarter 2020 Financial Results and Provides General Business Update
markets.businessinsider.com - November 5 at 6:11 AM
Karuna Therapeutics IncKaruna Therapeutics Inc
bloomberg.com - October 29 at 12:16 AM
Digging Deeper Into Karuna TherapeuticsDigging Deeper Into Karuna Therapeutics
seekingalpha.com - October 20 at 7:38 AM
Here's Why We're Not At All Concerned With Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn SituationHere's Why We're Not At All Concerned With Karuna Therapeutics' (NASDAQ:KRTX) Cash Burn Situation
finance.yahoo.com - September 22 at 2:05 PM
Thursday 9/10 Insider Buying Report: KRTX, EPDThursday 9/10 Insider Buying Report: KRTX, EPD
marketwatch.com - September 10 at 1:50 PM
Karuna Therapeutics Becomes Oversold (KRTX)Karuna Therapeutics Becomes Oversold (KRTX)
nasdaq.com - September 1 at 1:48 PM
Karuna Therapeutics Appoints Laurie Olson to Board of DirectorsKaruna Therapeutics Appoints Laurie Olson to Board of Directors
finance.yahoo.com - August 13 at 8:52 AM
Karuna Therapeutics Reports Second Quarter 2020 Financial Results and Business HighlightsKaruna Therapeutics Reports Second Quarter 2020 Financial Results and Business Highlights
finance.yahoo.com - August 5 at 10:14 AM
Karuna Therapeutics will not develop KarXT in PainKaruna Therapeutics will not develop KarXT in Pain
seekingalpha.com - August 3 at 7:47 PM
Karuna Therapeutics Announces Topline Data From Phase 1b Trial Evaluating KarXT on Experimentally Induced Pain in Healthy VolunteersKaruna Therapeutics Announces Topline Data From Phase 1b Trial Evaluating KarXT on Experimentally Induced Pain in Healthy Volunteers
finance.yahoo.com - August 3 at 7:47 PM
Karuna Therapeutics inks new drug discovery dealKaruna Therapeutics inks new drug discovery deal
seekingalpha.com - July 28 at 1:42 PM
Karuna Therapeutics and PsychoGenics Announce Drug Discovery CollaborationKaruna Therapeutics and PsychoGenics Announce Drug Discovery Collaboration
finance.yahoo.com - July 28 at 8:42 AM
Karuna Therapeutics Larger Than S&P 500 Component Under ArmourKaruna Therapeutics Larger Than S&P 500 Component Under Armour
www.nasdaq.com - July 23 at 7:38 PM
Hedge Funds Keep Buying Karuna Therapeutics, Inc. (KRTX)Hedge Funds Keep Buying Karuna Therapeutics, Inc. (KRTX)
finance.yahoo.com - June 28 at 11:28 PM
Karuna Program Progress, And Other News: The Good, Bad And Ugly Of BiopharmaKaruna Program Progress, And Other News: The Good, Bad And Ugly Of Biopharma
seekingalpha.com - June 26 at 8:54 AM
Karuna Therapeutics, Inc. (NASDAQ:KRTX) Insiders Increased Their HoldingsKaruna Therapeutics, Inc. (NASDAQ:KRTX) Insiders Increased Their Holdings
finance.yahoo.com - June 24 at 9:45 AM
Karuna to advance lead drug into Phase 3 for psychosis in schizophrenia patientsKaruna to advance lead drug into Phase 3 for psychosis in schizophrenia patients
seekingalpha.com - June 23 at 9:11 AM
Karuna Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for KarXT for the Treatment of Acute Psychosis in Patients with SchizophreniaKaruna Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for KarXT for the Treatment of Acute Psychosis in Patients with Schizophrenia
www.businesswire.com - June 23 at 6:41 AM
Karuna Therapeutics (KRTX) StockKaruna Therapeutics (KRTX) Stock
markets.businessinsider.com - June 18 at 12:54 AM
Brokers upbeat on Karuna Therapeutics Inc despite economic uncertaintyBrokers upbeat on Karuna Therapeutics Inc despite economic uncertainty
uk.finance.yahoo.com - June 10 at 8:26 AM
Karuna Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare ConferenceKaruna Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference
finance.yahoo.com - June 3 at 8:03 AM
Karuna Therapeutics to Present Additional Data from the Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia at the American Society of ...Karuna Therapeutics to Present Additional Data from the Phase 2 Clinical Trial of KarXT for the Treatment of Psychosis in Patients with Schizophrenia at the American Society of ...
www.businesswire.com - May 27 at 9:14 AM
Surging Earnings Estimates Signal Good News for Karuna Therapeutics (KRTX)Surging Earnings Estimates Signal Good News for Karuna Therapeutics (KRTX)
www.nasdaq.com - May 20 at 12:16 PM
Karuna Therapeutics Reports First Quarter 2020 Financial Results and Provides General Business UpdateKaruna Therapeutics Reports First Quarter 2020 Financial Results and Provides General Business Update
finance.yahoo.com - May 7 at 8:07 AM
Karuna Therapeutics Appoints Christopher J. Coughlin to its Board of DirectorsKaruna Therapeutics Appoints Christopher J. Coughlin to its Board of Directors
finance.yahoo.com - April 28 at 11:01 AM
Karuna Therapeutics, Inc. (KRTX) Shares March Higher, Can It Continue?Karuna Therapeutics, Inc. (KRTX) Shares March Higher, Can It Continue?
finance.yahoo.com - April 22 at 11:47 AM
Hedge Funds Have Never Been This Bullish On Karuna Therapeutics, Inc. (KRTX)Hedge Funds Have Never Been This Bullish On Karuna Therapeutics, Inc. (KRTX)
finance.yahoo.com - April 7 at 9:35 PM
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.